Gerard Dijkstra

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9585352/publications.pdf

Version: 2024-02-01

239 papers	13,986 citations	36203 51 h-index	25716 108 g-index
244 all docs	244 docs citations	244 times ranked	18496 citing authors

#	Article	IF	Citations
1	Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Frontiers in Immunology, 2019, 10, 277.	2.2	1,956
2	Proton pump inhibitors affect the gut microbiome. Gut, 2016, 65, 740-748.	6.1	885
3	Angiotensinâ€converting enzyme 2 (<scp>ACE2</scp>), <scp>SARSâ€CoV</scp>â€2 and the pathophysiology of coronavirus disease 2019 (<scp>COVID</scp>â€19). Journal of Pathology, 2020, 251, 228-248.	2.1	791
4	Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut, 2018, 67, 108-119.	6.1	590
5	Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFÎ± therapy: results from the COIN study. Gut, 2014, 63, 72-79.	6.1	430
6	Impact of Human Granulocyte and Monocyte Isolation Procedures on Functional Studies. Vaccine Journal, 2012, 19, 1065-1074.	3.2	353
7	Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Science Translational Medicine, 2018, 10, .	5.8	351
8	Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Medicine, 2014, 6, 107.	3.6	322
9	Allogeneic Bone Marrowâ€“Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohnâ€™s Disease. Gastroenterology, 2015, 149, 918-927.e6.	0.6	261
10	Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet, The, 2017, 390, 959-968.	6.3	253
11	Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome. Gut, 2021, 70, 1287-1298.	6.1	246
12	Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 785-792.	3.7	196
13	Detection of infliximab levels and antiâ€infliximab antibodies: a comparison of three different assays. Alimentary Pharmacology and Therapeutics, 2012, 36, 765-771.	1.9	182
14	High frequency of early colorectal cancer in inflammatory bowel disease. Gut, 2008, 57, 1246-1251.	6.1	173
15	Oxidative Stress and Redox-Modulating Therapeutics in Inflammatory Bowel Disease. Trends in Molecular Medicine, 2020, 26, 1034-1046.	3.5	169
16	Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut, 2009, 58, 388-395.	6.1	162
17	Inflammatory Bowel Disease After Liver Transplantation: Risk Factors for Recurrence and De Novo Disease. American Journal of Transplantation, 2006, 6, 1422-1429.	2.6	155
18	Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitisAn unusual case of ascites. Gut, 2007, 57, 463-467.	6.1	142

#	Article	IF	Citations
19	Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. British Journal of Cancer, 2009, 101, 1671-1675.	2.9	141
20	Effects of active and passive smoking on disease course of CrohnÊ¼s disease and ulcerative colitis. Inflammatory Bowel Diseases, 2009, 15, 1199-1207.	0.9	140
21	Role of alkaline phosphatase in colitis in man and rats. Gut, 2009, 58, 379-387.	6.1	136
22	The role of gut microbiota in health and disease: InÂvitro modeling of host-microbe interactions at the aerobe-anaerobe interphase of the human gut. Anaerobe, 2017, 44, 3-12.	1.0	130
23	Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut, 2014, 63, 451-457.	6.1	128
24	Ustekinumab for Crohnâ€™s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. Journal of Crohn's and Colitis, 2020, 14, 33-45.	0.6	124
25	Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflammatory Bowel Diseases, 2007, 13, 710-720.	0.9	119
26	More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflammatory Bowel Diseases, 2009, 15, 1331-1336.	0.9	99
27	Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease. PLoS ONE, 2011, 6, e23745.	1.1	99
28	Genetic susceptibility has a more important role in pediatric-onset CrohnÊ¼s disease than in adult-onset CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2007, 13, 1083-1092.	0.9	97
29	Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets. PLoS ONE, 2015, 10, e0129076.	1.1	95
30	Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohnâ€™s disease patients with prior failure to antiâ€TNF treatment. Alimentary Pharmacology and Therapeutics, 2020, 52, 123-134.	1.9	92
31	Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Alimentary Pharmacology and Therapeutics, 2003, 18, 33-44.	1.9	91
32	Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up. PLoS ONE, 2016, 11, e0142481.	1.1	89
33	Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study. Inflammatory Bowel Diseases, 2011, 17, 1837-1845.	0.9	88
34	In vivo monitoring of extracellular glutamate in the brain with a microsensor. Brain Research, 2006, 1118, 34-42.	1.1	83
35	Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohnâ€™s Disease Perianal Fistulas. Journal of Crohn's and Colitis, 2020, 14, 64-70.	0.6	80
36	TheATG16L1â€“T300Aallele impairs clearance of pathosymbionts in the inflamed ileal mucosa of Crohn's disease patients. Gut, 2015, 64, 1546-1552.	6.1	77

#	Article	IF	Citations
37	Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2017, 23, 1499-1509.	0.9	76
38	Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 900-907.	3.7	75
39	Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Antiâ€"Tumor Necrosis Factor-Î± Agents. Clinical Gastroenterology and Hepatology, 2013, 11, 826-831.	2.4	72
40	Calprotectin. Annals of Surgery, 2007, 246, 311-315.	2.1	69
41	Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohnâ€™s Disease from Ulcerative Colitis. Journal of Crohn's and Colitis, 2015, 9, 863-872.	0.6	69
42	The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1. BMC Gastroenterology, 2019, 19, 5.	0.8	68
43	Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity. Clinical Gastroenterology and Hepatology, 2017, 15, 1742-1749.e2.	2.4	65
44	Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Alimentary Pharmacology and Therapeutics, 2020, 51, 880-888.	1.9	64
45	Riboflavin Supplementation in Patients with Crohnâ€™s Disease [the RISE-UP study]. Journal of Crohn's and Colitis, 2020, 14, 595-607.	0.6	63
46	Functional Characterization of Mutations in the Myosin Vb Gene Associated With Microvillus Inclusion Disease. Journal of Pediatric Gastroenterology and Nutrition, 2011, 52, 307-313.	0.9	62
47	High prevalence of cachexia in newly diagnosed head and neck cancer patients: An exploratory study. Nutrition, 2017, 35, 114-118.	1.1	59
48	Single-Cell RNA Sequencing of Blood and Ileal T Cells From Patients With Crohn's Disease Reveals Tissue-Specific Characteristics and Drug Targets. Gastroenterology, 2019, 156, 812-815.e22.	0.6	58
49	A simple coculture system shows mutualism between anaerobic faecalibacteria and epithelial Caco-2 cells. Scientific Reports, 2016, 5, 17906.	1.6	57
50	Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. Alimentary Pharmacology and Therapeutics, 2015, 42, 529-539.	1.9	56
51	Small bowel preservation for intestinal transplantation: a review. Transplant International, 2011, 24, 107-131.	0.8	54
52	PREDICTION OF RECURRENT CYTOMEGALOVIRUS DISEASE AFTER TREATMENT WITH GANCICLOVIR IN SOLID-ORGAN TRANSPLANT RECIPIENTS. Transplantation, 1993, 55, 847-850.	0.5	53
53	Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies. Inflammatory Bowel Diseases, 2018, 24, 1298-1306.	0.9	53
54	Risk factors of work disability in patients with inflammatory bowel disease â€" A Dutch nationwide web-based survey. Journal of Crohn's and Colitis, 2014, 8, 590-597.	0.6	52

#	Article	IF	Citations
55	Long noncoding RNA H19X is a key mediator of TGF-Î²â€“driven fibrosis. Journal of Clinical Investigation, 2020, 130, 4888-4905.	3.9	52
56	Review: Local Tumor Necrosis Factor-Î± Inhibition in Inflammatory Bowel Disease. Pharmaceutics, 2020, 12, 539.	2.0	50
57	Food and Food Groups in Inflammatory Bowel Disease (IBD): The Design of the Groningen Anti-Inflammatory Diet (GrAID). Nutrients, 2021, 13, 1067.	1.7	50
58	Malignant transformation of perianal and enterocutaneous fistulas is rare: results of 17 years of follow-up from The Netherlands. Scandinavian Journal of Gastroenterology, 2011, 46, 319-325.	0.6	49
59	Performance of the Montreal classification for inflammatory bowel diseases. World Journal of Gastroenterology, 2014, 20, 15374.	1.4	49
60	Misbalance in type <scp>III</scp> collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 26-39.	1.9	49
61	Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial. Clinical Gastroenterology and Hepatology, 2020, 18, 1744-1752.	2.4	49
62	Crohn's Disease Patients Have More IgG-Binding Fecal Bacteria than Controls. Vaccine Journal, 2012, 19, 515-521.	3.2	46
63	Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 455-461.	0.6	46
64	Self-reported Disability in Patients with Inflammatory Bowel Disease Largely Determined by Disease Activity and Illness Perceptions. Inflammatory Bowel Diseases, 2015, 21, 369-377.	0.9	45
65	Prevention of postoperative recurrence of Crohn's disease. Journal of Crohn's and Colitis, 2012, 6, 637-646.	0.6	42
66	Increased Expression of Inducible Nitric Oxide Synthase in Circulating Monocytes from Patients with Active Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology, 2002, 37, 546-554.	0.6	40
67	Matrix metalloproteinases as profibrotic factors in terminal ileum in CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2006, 12, 863-869.	0.9	40
68	Westernized high-fat diet accelerates weight loss in dextran sulfate sodium-induced colitis in mice, which is further aggravated by supplementation of heme. Journal of Nutritional Biochemistry, 2013, 24, 1159-1165.	1.9	40
69	Multimodal treatment of perianal fistulas in Crohnâ€™s disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial. Trials, 2015, 16, 366.	0.7	40
70	Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. Gut, 2021, 70, 1266-1274.	6.1	40
71	Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human) Tj ETQq1 1 0.784314 rgBT /Over Inflammatory Bowel Diseases, 2010, 16, 1708-1716.	0.9	39
72	Genetic Analysis in A Dutch Study Sample Identifies More Ulcerative Colitis Susceptibility Loci and Shows Their Additive Role in Disease Risk. American Journal of Gastroenterology, 2010, 105, 395-402.	0.2	39

#	Article	IF	Citations
73	Identification of Clinical and Genetic Parameters Associated with Hidradenitis Suppurativa in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 106-113.	0.9	39
74	Anti-inflammatory Gut Microbial Pathways Are Decreased During Crohnâ€™s Disease Exacerbations. Journal of Crohn's and Colitis, 2019, 13, 1439-1449.	0.6	39
75	Absence of association between the multidrug resistance (MDR1) gene and inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2006, 41, 1174-1182.	0.6	38
76	Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 1568-1576.	0.9	38
77	A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease. Frontiers in Medicine, 2019, 6, 251.	1.2	37
78	Western and Carnivorous Dietary Patterns are Associated with Greater Likelihood of IBD Development in a Large Prospective Population-based Cohort. Journal of Crohn's and Colitis, 2022, 16, 931-939.	0.6	37
79	Cost-effectiveness of intestinal transplantation for adult patients with intestinal failure: a simulation study. American Journal of Clinical Nutrition, 2015, 101, 79-86.	2.2	36
80	Crohnâ€™s Disease in Clinical Remission Is Marked by Systemic Oxidative Stress. Frontiers in Physiology, 2019, 10, 499.	1.3	36
81	Guidelines for treatment with infliximab for Crohn's disease. Netherlands Journal of Medicine, 2006, 64, 219-29.	0.6	36
82	Monitoring extracellular glutamate in hippocampal slices with a microsensor. Journal of Neuroscience Methods, 2007, 160, 37-44.	1.3	35
83	Vitamin C Supplementation in Healthy Individuals Leads to Shifts of Bacterial Populations in the Gutâ€”A Pilot Study. Antioxidants, 2021, 10, 1278.	2.2	35
84	Increased fecal calprotectin levels in Crohnâ€™s disease correlate with elevated serum Th1- and Th17-associated cytokines. PLoS ONE, 2018, 13, e0193202.	1.1	34
85	Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis. Inflammatory Bowel Diseases, 2007, 13, 753-758.	0.9	33
86	Diffuse enteritis after colectomy for ulcerative colitis: two case reports and review of the literature. European Journal of Gastroenterology and Hepatology, 2009, 21, 710-715.	0.8	33
87	Mechanisms of Cell Polarityâ€“Controlled Epithelial Homeostasis and Immunity in the Intestine. Cold Spring Harbor Perspectives in Biology, 2017, 9, a027888.	2.3	33
88	Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease. BMJ Open, 2017, 7, e016695.	0.8	33
89	Inflammatory bowel disease after liver transplantation: A role for cytomegalovirus infection. Scandinavian Journal of Gastroenterology, 2006, 41, 205-211.	0.6	32
90	Evidence for Local Expansion of IgA Plasma Cell Precursors in Human Ileum. Journal of Immunology, 2009, 183, 4871-4878.	0.4	32

#	Article	IF	Citations
91	Monocytes and their pathophysiological role in Crohnâ€™s disease. Cellular and Molecular Life Sciences, 2009, 66, 192-202.	2.4	31
92	Pirfenidone Inhibits Cell Proliferation and Collagen I Production of Primary Human Intestinal Fibroblasts. Cells, 2020, 9, 775.	1.8	31
93	Up-regulation and Cytoprotective Role of Epithelial Multidrug Resistance-associated Protein 1 in Inflammatory Bowel Disease. Journal of Biological Chemistry, 2008, 283, 35630-35637.	1.6	30
94	Suppression of p21Rac Signaling and Increased Innate Immunity Mediate Remission in Crohnâ€™s Disease. Science Translational Medicine, 2014, 6, 233ra53.	5.8	30
95	Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouchâ€“Anal Anastomosis, Ileostomy and Anti-TNFÎ± Therapy. Journal of Crohn's and Colitis, 2015, 9, 1016-1023.	0.6	30
96	Runt-related transcription factor 3 is associated with ulcerative colitis and shows epistasis with solute carrier family 22, members 4 and 5. Inflammatory Bowel Diseases, 2008, 14, 1615-1622.	0.9	29
97	JC Virus Infection in Colorectal Neoplasia That Develops after Liver Transplantation. Clinical Cancer Research, 2008, 14, 6717-6721.	3.2	29
98	Intestinal Activation of pH-Sensing Receptor OGR1 [GPR68] Contributes to Fibrogenesis. Journal of Crohn's and Colitis, 2018, 12, 1348-1358.	0.6	29
99	Serum Free Thiols Are Superior to Fecal Calprotectin in Reflecting Endoscopic Disease Activity in Inflammatory Bowel Disease. Antioxidants, 2019, 8, 351.	2.2	29
100	Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumabâ€•and ustekinumabâ€treated patients with inflammatory bowel diseaseâ€”a prospective multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2020, 52, 1366-1376.	1.9	28
101	Biallelic variants in LIG3 cause a novel mitochondrial neurogastrointestinal encephalomyopathy. Brain, 2021, 144, 1451-1466.	3.7	28
102	Dietary Intake Pattern is Associated with Occurrence of Flares in IBD Patients. Journal of Crohn's and Colitis, 2021, 15, 1305-1315.	0.6	28
103	Whole exome sequencing analyses reveal geneâ€“microbiota interactions in the context of IBD. Gut, 2021, 70, gutjnl-2019-319706.	6.1	26
104	Targeting nitric oxide in the gastrointestinal tract. Current Opinion in Investigational Drugs, 2004, 5, 529-36.	2.3	26
105	Effects of active and passive smoking on Crohn's disease and ulcerative colitis in a cohort from a regional hospital. European Journal of Gastroenterology and Hepatology, 2011, 23, 255-261.	0.8	25
106	Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice. International Journal of Pharmaceutics, 2019, 554, 366-375.	2.6	25
107	Effects of different immunosuppressive regimens on regulatory T-cells in noninflamed colon of liver transplant recipients. Inflammatory Bowel Diseases, 2007, 13, 703-709.	0.9	24
108	Active and passive smoking behaviour and cessation plans of patients with Crohn's disease and ulcerative colitis. Journal of Crohn's and Colitis, 2010, 4, 125-131.	0.6	24

#	Article	IF	Citations
109	Dietary heme adversely affects experimental colitis in rats, despite heat-shock protein induction. Nutrition, 2011, 27, 590-597.	1.1	24
110	Predicting Endoscopic Disease Activity in CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2015, 21, 1.	0.9	24
111	The Oxysterol Synthesising Enzyme CH25H Contributes to the Development of Intestinal Fibrosis. Journal of Crohn's and Colitis, 2019, 13, 1186-1200.	0.6	24
112	Vedolizumab for Inflammatory Bowel Disease: Twoâ€Year Results of theÂInitiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study. Clinical Pharmacology and Therapeutics, 2020, 107, 1189-1199.	2.3	24
113	ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability. Journal of Controlled Release, 2013, 172, 618-624.	4.8	23
114	Nodular regenerative hyperplasia rarely leads to liver transplantation: A 20â€year cohort study in all Dutch liver transplant units. United European Gastroenterology Journal, 2017, 5, 658-667.	1.6	23
115	Identification of Environmental Risk Factors Associated With the Development of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2020, 14, 1662-1671.	0.6	23
116	Screening prior to biological therapy in Crohn's disease: Adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. Digestive and Liver Disease, 2014, 46, 881-886.	0.4	22
117	Habitual dietary intake of IBD patients differs from population controls: a caseâ€“control study. European Journal of Nutrition, 2021, 60, 345-356.	1.8	22
118	Ustekinuma b for Crohnâ€™s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. Journal of Crohn's and Colitis, 2021, 15, 1920-1930.	0.6	22
119	Haplotype-based analysis of ulcerative colitis risk loci identifies both IL2 and IL21 as susceptibility genes in Han Chinese. Inflammatory Bowel Diseases, 2011, 17, 2472-2479.	0.9	21
120	Adenomas in Patients with Inflammatory Bowel Disease Are Associated with an Increased Risk of Advanced Neoplasia. Inflammatory Bowel Diseases, 2013, 19, 342-349.	0.9	21
121	Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35â€…mg once weekly or placebo, concomitant with calcium and vitamin D supplementation. Gut, 2014, 63, 1424-1430.	6.1	21
122	Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease. Annals of Surgery, 2021, 273, 557-563.	2.1	21
123	Pooled Resequencing of 122 Ulcerative Colitis Genes in a Large Dutch Cohort Suggests Population-Specific Associations of Rare Variants in MUC2. PLoS ONE, 2016, 11, e0159609.	1.1	21
124	Titres of anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease are not related to disease activity. QJM - Monthly Journal of the Association of Physicians, 1999, 92, 651-658.	0.2	20
125	Synthesis and evaluation of a fluorine-18 labeled antisense oligonucleotide as a potential PET tracer for iNOS mRNA expression. Nuclear Medicine and Biology, 2004, 31, 605-612.	0.3	20
126	Correlation of Genetic Risk and Messenger RNA Expression in a Th17/IL23 Pathway Analysis in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 777-782.	0.9	20

#	Article	IF	Citations
127	Realâ€life study of safety of thiopurineâ€allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment. Alimentary Pharmacology and Therapeutics, 2019, 50, 407-415.	1.9	20
128	High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohnâ€™s Disease in a Randomized Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology, 2021, 19, 1573-1582.e5.	2.4	20
129	Association of interleukin-1 receptor-associated kinase M (IRAK-M) and inflammatory bowel diseases. Scandinavian Journal of Gastroenterology, 2007, 42, 827-833.	0.6	19
130	Early bacterial dependent induction of inducible nitric oxide synthase (iNOS) in epithelial cells upon transfer of CD45RBhigh CD4+ T cells in a model for experimental colitis. Inflammatory Bowel Diseases, 2007, 13, 1467-1474.	0.9	19
131	Presentation of a nationwide multicenter registry of intestinal failure and intestinal transplantation. Clinical Nutrition, 2016, 35, 225-229.	2.3	18
132	A comparative analysis of tioguanine versus lowâ€dose thiopurines combined with allopurinol in inflammatory bowel disease patients. Alimentary Pharmacology and Therapeutics, 2020, 51, 1076-1086.	1.9	18
133	Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease. World Journal of Gastroenterology, 2017, 23, 8182-8192.	1.4	18
134	Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2017, 11, jjw160.	0.6	17
135	Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process. Pharmaceutics, 2019, 11, 428.	2.0	17
136	Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 1105-1115.	1.9	17
137	Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1954-1962.	0.9	17
138	Current understanding of alloimmunity of the intestinal graft. Current Opinion in Organ Transplantation, 2015, 20, 286-294.	0.8	16
139	HSPA6 is an ulcerative colitis susceptibility factor that is induced by cigarette smoke and protects intestinal epithelial cells by stabilizing anti-apoptotic Bcl-XL. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 788-796.	1.8	16
140	Genomic and Expression Analyses Identify a Disease-Modifying Variant for Fibrostenotic Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2018, 12, 582-588.	0.6	16
141	Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ). Journal of Gastroenterology, 2019, 54, 238-248.	2.3	16
142	Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study. Clinical and Translational Gastroenterology, 2020, 11, e00217.	1.3	16
143	Inflammation status modulates the effect of host genetic variation on intestinal gene expression in inflammatory bowel disease. Nature Communications, 2021, 12, 1122.	5.8	16
144	Effect of Aging on Healthcare Costs of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 637-645.	0.9	15

#	Article	IF	Citations
145	Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients. Clinical Gastroenterology and Hepatology, 2019, 17, 568-570.	2.4	15
146	Assessing intestinal permeability in Crohnâ€™s disease patients using orally administered 52Cr-EDTA. PLoS ONE, 2019, 14, e0211973.	1.1	15
147	Intestinal rehabilitation for children with intestinal failure is cost-effective: a simulation study. American Journal of Clinical Nutrition, 2017, 105, 417-425.	2.2	14
148	Senescent Stem and Transient Amplifying Cells in Crohnâ€™s Disease Intestine. Inflammatory Bowel Diseases, 2020, 26, e8-e9.	0.9	14
149	Safe and Successful Treatment of Acute Cellular Rejection of an Intestine and Abdominal Wall Transplant With Vedolizumab. Transplantation Direct, 2020, 6, e527.	0.8	14
150	Are all dietary fibers equal for patients with inflammatory bowel disease? A systematic review of randomized controlled trials. Nutrition Reviews, 2022, 80, 1179-1193.	2.6	14
151	The Effect of Phenotype and Genotype on the Plasma Proteome in Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, 414-429.	0.6	13
152	Histopathologic and molecular evaluation of the Organ Procurement and Transplantation Network selection criteria for intestinal graft donation. Journal of Surgical Research, 2014, 189, 143-151.	0.8	12
153	Cigarette Smoke Increases Risk for Colorectal Neoplasia in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 798-805.e1.	2.4	12
154	Bioelectrical Impedance Analysis and Mid-Upper Arm Muscle Circumference Can Be Used to Detect Low Muscle Mass in Clinical Practice. Nutrients, 2021, 13, 2350.	1.7	12
155	Inulin-grown Faecalibacterium prausnitzii cross-feeds fructose to the human intestinal epithelium. Gut Microbes, 2021, 13, 1993582.	4.3	12
156	Patients With Inflammatory Bowel Disease Show IgG Immune Responses Towards Specific Intestinal Bacterial Genera. Frontiers in Immunology, 0, 13, .	2.2	12
157	Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating CrohnÊ¼s disease. Alimentary Pharmacology and Therapeutics, 2022, 56, 675-693.	1.9	12
158	Thiopurines Are Associated with a Reduction in Surgical Re-resections in Patients with CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2013, 19, 2801-2808.	0.9	11
159	Lymphoproliferative Disease in the Rectum 4 Years After Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohnâ€™s Fistulas: A Case Report. Journal of Crohn's and Colitis, 2019, 13, 807-811.	0.6	11
160	Endoscopic imaging in inflammatory bowel disease: current developments and emerging strategies. Expert Review of Gastroenterology and Hepatology, 2021, 15, 115-126.	1.4	11
161	Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8â€‰+â€‰T cells and an infiltration pattern that resembles ulcerative colitis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1119-1129.	1.4	11
162	SLC39A8 missense variant is associated with Crohn's disease but does not have a major impact on gut microbiome composition in healthy subjects. PLoS ONE, 2019, 14, e0211328.	1.1	10

#	Article	IF	Citations
163	Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study. Journal of Crohn's and Colitis, 2021, 15, 1464-1473.	0.6	10
164	New Therapeutic Approach for Intestinal Fibrosis Through Inhibition of pH-Sensing Receptor GPR4. Inflammatory Bowel Diseases, 2022, 28, 109-125.	0.9	10
165	The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFÎ± Treatment in Crohnâ€™s Disease. Journal of Clinical Gastroenterology, 2021, 55, 59-66.	1.1	10
166	Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. Journal of Thrombosis and Thrombolysis, 2007, 24, 175-182.	1.0	9
167	Cytomegalovirus Infection Increases the Risk for Inflammatory Bowel Disease. American Journal of Pathology, 2010, 176, 3098.	1.9	9
168	Nutritional Assessment in Inflammatory Bowel Disease (IBD)â€"Development of the Groningen IBD Nutritional Questionnaires (GINQ). Nutrients, 2019, 11, 2739.	1.7	9
169	Abdominal Wall Transplantation: Indications and Outcomes. Current Transplantation Reports, 2020, 7, 279-290.	0.9	9
170	Intestinal stenosis in Crohnâ€™s disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482095257.	1.4	9
171	Trajectories of Fatigue in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1919-1930.	0.9	9
172	A Non-Invasive, Low-Cost Study Design to Determine the Release Profile of Colon Drug Delivery Systems: A Feasibility Study. Pharmaceutical Research, 2012, 29, 2070-2078.	1.7	8
173	Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes. Journal of Crohn's and Colitis, 2021, 15, 930-937.	0.6	8
174	HIF1Î±-Dependent Induction of TFRC by a Combination of Intestinal Inflammation and Systemic Iron Deficiency in Inflammatory Bowel Disease. Frontiers in Physiology, 0, 13, .	1.3	8
175	The Impact of Ethnicity and Country of Birth on Inflammatory Bowel Disease Phenotype: a Prospective Cohort Study. Journal of Crohn's and Colitis, 2017, 11, 1463-1470.	0.6	7
176	Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. Inflammatory Bowel Diseases, 2018, 24, 1558-1565.	0.9	7
177	Levels of Anti-Citrullinated Protein Antibodies and Rheumatoid Factor, Including IgA Isotypes, and Articular Manifestations in Ulcerative Colitis and Crohnâ€™s Disease. International Journal of Environmental Research and Public Health, 2020, 17, 8054.	1.2	7
178	Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110125.	1.4	7
179	Letter: detection of infliximab levels and antiâ€infliximab antibodies â€“ comparison of three different assays; authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2013, 37, 282-282.	1.9	6
180	Offâ€label prescriptions of drugs used for the treatment of Crohnâ€™s disease or ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2019, 49, 1293-1300.	1.9	6

#	Article	IF	Citations
181	Isotype-specific Antibody Responses to Mycobacterium avium paratuberculosis Antigens Are Associated With the Use of Biologic Therapy in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 1253-1263.	0.6	6
182	Bone cells from patients with quiescent Crohn's disease show a reduced growth potential and an impeded maturation. Journal of Cellular Biochemistry, 2012, 113, 2424-2431.	1.2	5
183	Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study. Scandinavian Journal of Gastroenterology, 2015, 50, 399-405.	0.6	5
184	Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients. Alimentary Pharmacology and Therapeutics, 2020, 51, 1353-1364.	1.9	5
185	Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial. BMJ Open, 2021, 11, e054154.	0.8	5
186	Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-Î± biologicals and an Infliximab-biosimilar. PLoS ONE, 2018, 13, e0208922.	1.1	4
187	Development and Characterisation of Antibody-Based Optical Imaging Probes for Inflammatory Bowel Disease. Pharmaceuticals, 2021, 14, 922.	1.7	4
188	A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease. Gut Microbes, 2021, 13, 1943288.	4.3	4
189	Long-Term Dietary Patterns Are Reflected in the Plasma Inflammatory Proteome of Patients with Inflammatory Bowel Disease. Nutrients, 2022, 14, 2522.	1.7	4
190	Vulvar and vaginal neoplasia in women with inflammatory bowel disease. Digestive and Liver Disease, 2020, 52, 149-155.	0.4	3
191	IGLâ€‰ as a preservation solution in intestinal transplantation: a multicenter experience. Transplant International, 2020, 33, 963-965.	0.8	3
192	Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease. Journal of Drug Delivery Science and Technology, 2021, 64, 102552.	1.4	3
193	Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFÎ± therapy in inflammatory bowel disease. PLoS ONE, 2021, 16, e0256860.	1.1	3
194	Microscopic colitis: an unfamiliar but treatable disease. Netherlands Journal of Medicine, 2009, 67, 41-5.	0.6	3
195	Mantle cell lymphoma involving the appendiceal orifice as an unusual cause of lower gastrointestinal bleeding. International Journal of Colorectal Disease, 2006, 22, 99-100.	1.0	2
196	Latent cytomegalovirus infection does not influence long-term disease outcomes in inflammatory bowel disease, but is associated with later onset of disease. Scandinavian Journal of Gastroenterology, 2020, 55, 891-896.	0.6	2
197	Environmental factors associated with biological use and surgery in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1022-1034.	1.4	2
198	SMART-IBD: Better Health Care from the Patientâ€™s Perspective. , 2021, , 87-93.		2

#	Article	IF	Citations
199	P284 Prophylactic medication for the prevention of endoscopic recurrence after ileocolonic resection in Crohnâ€™s disease: a prospective study based on clinical risk stratification. Journal of Crohn's and Colitis, 2022, 16, i316-i317.	0.6	2
200	Indications, Postoperative Management, and Long-term Prognosis of Crohnâ€™s Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West. Inflammatory Bowel Diseases, 2022, 28, S16-S24.	0.9	2
201	Lithium induces intestinothrophic effects in the healthy colon, but does not ameliorate dextran sulfate sodium-induced colitis in mice. E-SPEN Journal, 2012, 7, e16-e22.	0.5	1
202	P464 Switching from the originator infliximab to biosimilar CT-P13 did not change the quality of life and clinical efficacy for IBD patients in stable remission in daily clinical practice (interim analysis). Journal of Crohn's and Colitis, 2018, 12, S339-S340.	0.6	1
203	DOP20 Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicine. Journal of Crohn's and Colitis, 2020, 14, S059-S060.	0.6	1
204	OP39 The effect of phenotype and genotype on the plasma proteome in patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, S036-S039.	0.6	1
205	P509 Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohnâ€™s disease. Journal of Crohn's and Colitis, 2022, 16, i468-i469.	0.6	1
206	DOP15 Fluorescent labelled vedolizumab for real-time visualization and quantification of local drug distribution and pharmacodynamics in Inflammatory Bowel Diseases during endoscopy. Journal of Crohn's and Colitis, 2022, 16, i064-i065.	0.6	1
207	DOP63 Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, i108-i109.	0.6	1
208	P606 Use of TNF-Î±-antagonists and systemic steroids is associated with attenuated immunogenicity against SARS-CoV-2 in fully vaccinated patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, i538-i538.	0.6	1
209	P577 Mucosal eosinophil abundance in non-inflamed colonic tissue predict response to vedolizumab induction therapy in inflammatory bowel disease. Journal of Crohn's and Colitis, 2022, 16, i517-i518.	0.6	1
210	Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease. Journal of Clinical Medicine, 2022, 11, 4141.	1.0	1
211	Inducible nitric oxide synthase is expressed on peripheral monocytes of patients with active inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 1998, 10, A45.	0.8	0
212	Treatment of ulcerative colitis with mesalazine, prednisolon and azathioprine in a pregnant patient complicated by a primary cytomegalovirus infection. European Journal of Gastroenterology and Hepatology, 1998, 10, A90.	0.8	0
213	Cytoprotective role of Multidrug Resistance associated Protein (MRP1) in severe intestinal inflammation: involvement of the leukotriene pathway. European Journal of Gastroenterology and Hepatology, 2006, 18, A62-A63.	0.8	0
214	Susceptibility Genes in Pediatric-onset IBD Compared with Healthy Controls and Adult-onset IBD. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, S43.	0.9	0
215	Letter: infliximab therapy for patients with inflammatory bowel disease â€“ some unanswered questions. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2015, 42, 1134-1134.	1.9	0
216	Preface. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 143-144.	1.0	0

#	Article	IF	Citations
217	A Regular Diet with Supplements is Sufficient for Intestinal Transplant Recipients. Transplantation, 2017, 101, S147.	0.5	0
218	MON-P071: Increase in BMI after Intestinal Transplantation (ITX) in Adults without Total Parenteral Nutrition (TPN). Clinical Nutrition, 2017, 36, S205-S206.	2.3	0
219	OP0086â€...Long noncoding RNA H19X as a new therapeutic target for fibrosis. , 2017, , .		0
220	P374 Home or hospital-based analysis of stool calprotectin: assessing two methods for monitoring inflammatory bowel disease. Journal of Crohn's and Colitis, 2017, 11, S268-S268.	0.6	0
221	DOP051 Serological biomarkers of tissue turnover can early identify responders to infliximab in Crohn's disease. Journal of Crohn's and Colitis, 2017, 11, S57-S57.	0.6	0
222	P815 How to measure environmental exposures (the exposome) in inflammatory bowel disease?. Journal of Crohn's and Colitis, 2018, 12, S525-S526.	0.6	0
223	OP01 In-depth characterisation of host genetics and gut microbiome unravels novel hostâ€“microbiome interactions in inflammatory bowel disease. Journal of Crohn's and Colitis, 2019, 13, S001-S001.	0.6	0
224	P166 A combined set of four serum inflammatory biomarkers reliably predicts endoscopic disease activity in inflammatory bowel disease. Journal of Crohn's and Colitis, 2019, 13, S172-S172.	0.6	0
225	P784 Prevalence of cervical dysplasia in women with inflammatory bowel disease: data from the Parelsnoer Institute (PSI) and PALGA database (PAP-IBD study). Journal of Crohn's and Colitis, 2019, 13, S513-S513.	0.6	0
226	DOP24 Intestinal acidification sensed by pH-sensing receptor GPR4 contributes to fibrogenesis. Journal of Crohn's and Colitis, 2019, 13, S039-S039.	0.6	0
227	P4.29: Vedolizumab for chronic allograft enteropathy? A case report. Transplantation, 2019, 103, S155-S155.	0.5	0
228	P184 Temporary defunctioning ileostomy in therapy refractory Crohnâ€™s colitis: A viable alternative to immediate colorectal resection?. Journal of Crohn's and Colitis, 2020, 14, S230-S231.	0.6	0
229	Switching from Reference Infliximab to Biosimilar CT-P13 did not Change Quality of Life in Stable Inflammatory Bowel Disease Patients. Crohn's & Colitis 360, 0, , .	0.5	0
230	P394 Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, S403-S404.	0.6	0
231	P339 Pregnant women with perianal Crohnâ€™s Disease: suggestions for the improvement of the current guideline on delivery method. Journal of Crohn's and Colitis, 2021, 15, S364-S364.	0.6	0
232	Change in liverfunction tests in patients switched form olive oil based tpn to fish oil containing tpn. Clinical Nutrition ESPEN, 2021, 46, S782.	0.5	0
233	P126 The predictive value of the modified Rutgeerts score at index endoscopy after primary ileocolic resection in patients with Crohnâ€™s disease for the risk of re-resection and severe endoscopic inflammation after long-term follow-up. Journal of Crohn's and Colitis, 2022, 16, i214-i214.	0.6	0
234	DOP75 Effectiveness and Safety of tofacitinib versus vedolizumab in Patients with Ulcerative Colitis; A Nationwide, ICC Registry study. Journal of Crohn's and Colitis, 2022, 16, i118-i120.	0.6	0

#	Article	IF	Citations
235	P176 The effect of induction therapy with infliximab or vedolizumab on hepcidin and iron status in patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, i244-i245.	0.6	0
236	P611 Serological biomarkers of type VI and XXII collagen formation predict and monitor infliximab treatment response in patients with Crohnâ€™s disease. Journal of Crohn's and Colitis, 2022, 16, i541-i541.	0.6	0
237	P687 Prevalence of iron deficiency and anaemia in the outpatient Inflammatory Bowel Disease population: a Dutch national cross-sectional study. Journal of Crohn's and Colitis, 2022, 16, i589-i589.	0.6	0
238	HIGH INADEQUATE SURVEILLANCE RATES IN COLITIS-ASSOCIATED ADVANCED NEOPLASIA: A MULTICENTER RETROSPECTIVE STUDY. Gastrointestinal Endoscopy, 2022, 95, AB110-AB111.	0.5	0
239	The Effect of the COVID-19 Pandemic in Intestinal Rehabilitation and Transplant Patients: Initial Results of the Intestinal Rehabilitation and Transplant Associationâ€™s International Survey. Transplantation, 2022, 106, 1289-1292.	0.5	0